BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 24813561)

  • 1. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects.
    Lindegger N; Sidharta PN; Reseski K; Dingemanse J
    Pulm Pharmacol Ther; 2014 Oct; 29(1):41-8. PubMed ID: 24813561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
    Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
    Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
    Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
    Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan.
    Juif PE; Dingemanse J; Voors-Pette C; Ufer M
    AAPS J; 2020 Aug; 22(5):103. PubMed ID: 32748293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
    Stier B; Fossler M; Liu F; Caltabiano S
    Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
    Sidharta PN; van Giersbergen PL; Dingemanse J
    J Clin Pharmacol; 2013 Nov; 53(11):1131-8. PubMed ID: 23900878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan and morbidity and mortality in pulmonary arterial hypertension.
    Pulido T; Adzerikho I; Channick RN; Delcroix M; Galiè N; Ghofrani HA; Jansa P; Jing ZC; Le Brun FO; Mehta S; Mittelholzer CM; Perchenet L; Sastry BK; Sitbon O; Souza R; Torbicki A; Zeng X; Rubin LJ; Simonneau G;
    N Engl J Med; 2013 Aug; 369(9):809-18. PubMed ID: 23984728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravenous zanamivir on cardiac repolarization.
    Lou Y; Gan J; Peppercorn A; Gould E; Weller S; Piscitelli SC; Patel P
    Pharmacotherapy; 2013 Jul; 33(7):701-9. PubMed ID: 23553534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.
    Galiè N; Jansa P; Pulido T; Channick RN; Delcroix M; Ghofrani HA; Le Brun FO; Mehta S; Perchenet L; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Torbicki A
    Eur Heart J; 2017 Apr; 38(15):1147-1155. PubMed ID: 28329315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
    Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
    Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of macitentan for the treatment of pulmonary arterial hypertension.
    Selej M; Romero AJ; Channick RN; Clozel M
    Ann N Y Acad Sci; 2015 Nov; 1358():68-81. PubMed ID: 26291180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
    Avdeev SN
    Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
    Kori S; Kellerman DJ; Voloshko P; Haugen G
    Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.